Mohamed Guenena, MD
Ophthalmology · Derry, NHNPI 1730471459
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,290 of the $8,301 with a category attached, or 63.7%. It is spread thinly across 27 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2022 at $2,436 and has fallen 57.7% since, to $1,030 in 2025. Among ophthalmology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $55.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Alcon$2K
- Biotissue Holdings Inc.$1K
- AbbVie$603
- Optos, Inc.$370
- Rxsight Inc$323
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2,80534%
- Food & beverage$5,29064%
- Entertainment$2052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 5 | $1,769 |
| Alcon | 33 | $1,509 |
| Biotissue Holdings Inc. | 12 | $1,494 |
| AbbVie(2 entities) | 13 | $603 |
| Optos, Inc. | 2 | $370 |
| Rxsight Inc | 5 | $323 |
| Novartis | 16 | $313 |
| Amgen(2 entities) | 7 | $281 |
| Dompe US, Inc. | 5 | $233 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $178 |
| Eyepoint US, Inc. | 2 | $173 |
| Oyster Point Pharma, Inc. | 8 | $162 |
| Kala Pharmaceuticals, Inc. | 2 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $113 |
| Bausch & Lomb Americas Inc. | 5 | $102 |
| Tarsus Pharmaceuticals, Inc. | 4 | $94 |
| Sun Pharmaceutical Industries Inc. | 4 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $60 |
| Rayner Intraocular Lenses Limited | 3 | $57 |
| Glaukos Corporation | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $19 |
| Sight Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$1,645
- CLARUS$1,645
- FORUM$1,645
- Humphrey HFA$1,645
- IOLMaster 700$1,645
- PANORAMIC OPHTHALMOSCOPE$740
- OCT OPHTHALMOSCOPE$575
- Clareon$447
- NFC-700$370
- RXSIGHT CONTACT LENS$255
- RXSIGHT INJECTOR CARTRIDGE$255
- RXSIGHT INJECTOR HANDPIECE$255
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$255
- Rocklatan$216
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$150
- AcrySof IQ PanOptix$148
- ORA$131
- TRAVATAN Z$124
- INVELTYS$124
- RESTASIS$119
How this compares
$8,301 in reported general payments places this provider in the 90th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 60 | $51,833 |
| XiidraLifitegrast | 43 | $30,108 |
| LumiganBimatoprost | 44 | $16,938 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $10,597 |
| Cyclosporine | 19 | $6,101 |
| Alphagan PBrimonidine Tartrate | 14 | $4,874 |
| Prednisolone Acetate | 108 | $4,554 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,944 |
| Loteprednol Etabonate | 19 | $2,496 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $2,417 |
| Latanoprost | 325 | $1,803 |
| Timolol Maleate | 102 | $1,064 |
| Ketorolac Tromethamine | 42 | $1,037 |
| Brimonidine Tartrate | 47 | $901 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $603 | $84,241144 claims |
| Bausch & Lomb Americas Inc.Xiidra | $102 | $30,10843 claims |
| AlconSimbrinza | $1,509 | $2,94411 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $178 | $2,49619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Derry
- Dane SlentzDerry$127K
- Gerald SpindelDerry$7K
- David VazanDerry$3K
- Jason SzelogPortsmouth$71K
- Andrew CatomerisLebanon$56K
- Jennifer LingPortsmouth$9K
- John DagianisNashua$9K
- Ahad FazelatManchester$8K
- Heather BartelsPeterborough$8K
- Thamolwan SurakiatchanukulLebanon$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.